Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Korea United Pharm Inc. (033270:KRX), powered by AI.
Korea United Pharm Inc. is currently trading at ₩18,650. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Korea United Pharm Inc. on Alpha Lenz.
Korea United Pharm Inc.'s P/E ratio is 7.7.
“Korea United Pharm Inc. trades at a P/E of 7.7 (undervalued) with solid ROE of 8.9%.”
Ask for details →Korea United Pharm Inc. is a pharmaceutical company that develops, manufactures, and distributes a wide range of medicinal products. Its primary function is to enhance healthcare treatment options through the provision of high-quality pharmaceuticals, spanning categories such as prescription drugs, over-the-counter medications, and health supplements. The company is known for its advanced research and development capabilities, fostering the creation of innovative drugs aimed at treating various health conditions. With a focus on therapeutic areas like cardiovascular, gastrointestinal, and antibiotic therapies, Korea United Pharm Inc. significantly contributes to public health improvements. In the financial market, it represents a key player in the healthcare sector, responding to both domestic and international demands for effective and affordable medication. Headquartered in South Korea, the company leverages its strong production facilities and comprehensive distribution networks to ensure the sustained delivery of healthcare solutions. By maintaining robust collaboration within the global pharmaceutical community, Korea United Pharm Inc. bolsters its strategic position, influencing both market trends and regulatory practices within the sector.
“Korea United Pharm Inc. trades at a P/E of 7.7 (undervalued) with solid ROE of 8.9%.”
Ask for details →Korea United Pharm Inc. (ticker: 033270) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $296.7B.
The current price is ₩18,650 with a P/E ratio of 7.75x and P/B of 0.65x.
ROE is 8.90% and operating margin is 17.35%. Annual revenue is $288.8B.